On November 05, 2015 MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) reported upcoming presentations of data on the Company’s proprietary programs at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, being held December 5-8, 2015 in Orlando, Florida (Press release, MorphoSys, NOV 5, 2015, View Source [SID:1234508019]). Presentations will feature pre-clinical and clinical data for MorphoSys’s proprietary programs MOR208 and MOR202.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We believe the promising new pre-clinical and clinical data being presented for our proprietary portfolio will further demonstrate the potential of MOR208 and MOR202 as important treatment options for patients with B-cell malignancies and multiple myeloma, respectively," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We intend to start additional clinical trials of MOR208 in combination regimens to assess the potential benefit of such regimens for patients with CLL and DLBCL."
Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma
The poster presentation will include updated clinical results from the MOR208 monotherapy trial in adult patients with relapsed/refractory NHL.
Abstract #1528
Poster session 624: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models
Date: Saturday, December 5, 2015, 5:30pm – 7:30pm EST (11:30pm CET, 10:30pm GMT)
A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)
The poster presentation will include first safety and efficacy results from the ongoing trial of MOR208 in combination with lenalidomide.
Abstract #2953
Poster session 642: CLL: Therapy, excluding Transplantation
Date: Sunday, December 6, 2015, 6:00pm – 8:00pm EST (0:00 am CET (Dec. 7), 11:00pm GMT)
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed or Refractory Multiple Myeloma
The poster presentation will include updated safety and efficacy results from the ongoing MOR202 dose-escalation study in multiple myeloma patients. Data will be presented from the highest dose cohort of MOR202 as monotherapy, as well as from the first two cohorts of patients receiving MOR202 in combination with lenalidomide and pomalidomide.
Abstract #3035
Session Name: 653. Myeloma: Therapy, excluding Transplantation
Date: Sunday, December 6, 2015, 6:00pm – 8:00pm EST (0:00 am CET (Dec. 7), 11:00pm GMT)
MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds
Abstract #3015
Poster session 652: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
Date: Sunday, December 6, 2015, 6:00pm – 8:00pm EST (0:00 am CET (Dec. 7), 11:00pm GMT)
Lenalidomide enhances MOR202 dependent macrophage-mediated effector functions via the vitamin D pathway
Abstract #2203
Poster session 201: Granulocytes, Monocytes and Macrophages
Date: Sunday, December 6, 2015, 6:00pm – 8:00pm EST (0:00 am CET (Dec. 7), 11:00pm GMT)
Additional information can be found at www.hematology.org, including the abstracts.